6,537 Shares in CareDx, Inc (NASDAQ:CDNA) Acquired by Creative Planning

Creative Planning bought a new position in shares of CareDx, Inc (NASDAQ:CDNA) during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 6,537 shares of the company’s stock, valued at approximately $204,000.

A number of other large investors have also recently made changes to their positions in CDNA. GAMMA Investing LLC boosted its holdings in CareDx by 1,021.8% in the second quarter. GAMMA Investing LLC now owns 2,210 shares of the company’s stock valued at $34,000 after purchasing an additional 2,013 shares in the last quarter. Plato Investment Management Ltd acquired a new position in CareDx in the second quarter valued at approximately $62,000. CWM LLC boosted its holdings in CareDx by 560.1% in the third quarter. CWM LLC now owns 7,604 shares of the company’s stock valued at $237,000 after purchasing an additional 6,452 shares in the last quarter. Meeder Asset Management Inc. acquired a new position in CareDx in the second quarter valued at approximately $142,000. Finally, Allspring Global Investments Holdings LLC boosted its holdings in CareDx by 10,267.2% in the first quarter. Allspring Global Investments Holdings LLC now owns 18,661 shares of the company’s stock valued at $198,000 after purchasing an additional 18,481 shares in the last quarter.

Wall Street Analyst Weigh In

Several equities research analysts have recently weighed in on the company. StockNews.com raised CareDx from a “hold” rating to a “buy” rating in a report on Thursday, October 17th. Wells Fargo & Company began coverage on CareDx in a research note on Tuesday, August 27th. They set an “underweight” rating and a $28.00 price target for the company. BTIG Research cut their price objective on CareDx from $40.00 to $35.00 and set a “buy” rating for the company in a research report on Tuesday, November 5th. The Goldman Sachs Group raised their price target on CareDx from $26.00 to $35.00 and gave the company a “buy” rating in a research report on Wednesday, October 16th. Finally, Craig Hallum increased their price objective on CareDx from $22.00 to $32.00 and gave the company a “buy” rating in a research note on Thursday, August 1st. One analyst has rated the stock with a sell rating, two have given a hold rating and five have assigned a buy rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $29.60.

CareDx Stock Performance

CareDx stock opened at $23.34 on Tuesday. The stock’s 50 day moving average price is $27.28 and its 200 day moving average price is $21.29. The firm has a market capitalization of $1.25 billion, a PE ratio of -8.64 and a beta of 1.80. CareDx, Inc has a one year low of $7.09 and a one year high of $34.84.

CareDx (NASDAQ:CDNA) last announced its earnings results on Monday, November 4th. The company reported ($0.14) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.25) by $0.11. The company had revenue of $82.88 million for the quarter, compared to analyst estimates of $80.04 million. CareDx had a negative return on equity of 53.70% and a negative net margin of 45.90%. CareDx’s quarterly revenue was up 23.4% on a year-over-year basis. During the same period in the prior year, the company posted ($0.43) EPS. On average, analysts forecast that CareDx, Inc will post -0.83 earnings per share for the current fiscal year.

Insider Activity at CareDx

In related news, Director Peter Maag sold 35,552 shares of the company’s stock in a transaction on Tuesday, August 20th. The stock was sold at an average price of $33.04, for a total transaction of $1,174,638.08. Following the completion of the transaction, the director now directly owns 330,024 shares in the company, valued at $10,903,992.96. This represents a 0.00 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. In other news, insider Alexander L. Johnson sold 21,557 shares of the company’s stock in a transaction on Wednesday, August 21st. The stock was sold at an average price of $32.58, for a total transaction of $702,327.06. Following the completion of the sale, the insider now directly owns 284,983 shares of the company’s stock, valued at $9,284,746.14. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, Director Peter Maag sold 35,552 shares of the company’s stock in a transaction on Tuesday, August 20th. The shares were sold at an average price of $33.04, for a total value of $1,174,638.08. Following the sale, the director now directly owns 330,024 shares of the company’s stock, valued at approximately $10,903,992.96. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 91,340 shares of company stock valued at $3,025,415. Corporate insiders own 4.90% of the company’s stock.

About CareDx

CareDx, Inc engages in the discovery, development, and commercialization of diagnostic solutions for transplant patients and caregivers in the United States and internationally. It also provides AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution for heart transplant patients; and AlloSure Lung, a dd-cfDNA solution for lung transplant patients.